Attorneys For Asbestos Related Cases

Asbestos is not to be taken lightly. It is a very serious matter and lots of people have suffered greatly from it. There are attorneys that are specifically trained in dealing with asbestos cases. Asbestos is a fiber that is used in old buildings as an insulator. The tiny fibers look like little spikes and get down into your lungs and can suffocate a person and cause severe problems and sometimes even death. Medical bills can be rather unbelievable and there is no reason that someone should be stuck with them because a job failed to tell you the health risks and details of the job.
Lawyers that are specifically experienced in asbestos cases see the effects of exposure to it. The suffering that it causes and the lives that have been destroyed is something that touches these people and inspires them to help. Mesothelioma is the disease that is caused by asbestos. So many innocent people are suffering from this as a result of working hard at their jobs. They deserve compensation for their suffering and these lawyers will work hard to make sure they get everything they can for having gone through this.
There are three main types of Mesothelioma; Pleural, peritoneal and pericardial. These are all tumors that start to grow in the lungs. Attorneys are so serious about bringing you justice they can tell you every little tiny detail of asbestos and all of the diseases that come with it. If you are beginning to see symptoms you might want to take precautions or see a doctor and an attorney before it is too late.
It takes 20-45 years for symptoms to start showing, but some of the typical symptoms include shortness of breath, coughing chest pain or pain in the back and other areas, weight loss and fever. There are different symptoms for the different types of Mesothelioma as well. Your attorney can explain everything to you in great detail. There are other diseases that are related to asbestos exposure as well. Attorneys will represent you if you have any sort of related illnesses.
Health hazards of asbestos were recognized in the early 1900s. In the '30s it was already beginning to show up in medical journals that asbestos could cause cancer after a latency period of 15 years or more. Also it was written that it was a progressive disease and yes, fatal. Many asbestos companies kept notes on the danger of the exposure. Even though they knew how fatal it was they continued to keep this information from workers and let them continue to be exposed to it.

Article Source: http://EzineArticles.com

Chemoradiation In Cancer Therapy

Chemoradiation In Cancer Therapy

The medical uses of ionizing radiation have expanded dramatically since Wilhelm Roentgen first discovered it at the end of the last century. In particular, it has proven to be an effective agent in the ongoing battle against cancer. It is presumed that the essential target for radiation is cellular DNA where it acts through the formation of free radicals to directly or indirectly cause double-stranded breaks. It is these doublestranded breaks in the DNA that are felt to be the lethal lesion that malignant cells sustain from therapeutic radiation.

It was in the period of World War II that it was possible to induce lasting remissions

and potential cures of hematological malignancies with nitrogen mustard (1), which was

really the first chemotherapeutic agent put to widespread use in the treatment of malignant

disease. Since that time, a multitude of other drugs have come and gone in the search

for a cure. A few drugs appear to have found a more lasting place in the therapeutic

armamentarium, including doxorubicin, cisplatinum, cyclophosphamide, and 5-fluorouracil.

A new generation of drugs with varied mechanisms of action has appeared in

the last decade and also has the potential to remain as key in the treatment of cancers.

These agents include paclitaxel, docetaxel, gemcitabine, irinotecan, and vinorelbine.

Although oncologists and researchers have often tried to cure cancers with radiation

alone or with various chemotherapeutic strategies, in general these have been met with

limited success for any number of reasons, which will be outlined below. The strategy of

integrating different treatment modalities into a more comprehensive approach to both

local control and the treatment of micrometastatic disease, often referred to as combined

modality therapy, has been met with some success. Although the delivery of neoadjuvant

and adjuvant chemotherapy may contribute to improved local control, it is less clearly

demonstrable than with concurrent therapy. This chapter will focus on combined modality

therapy with an emphasis on concurrent chemoradiation. It will attempt to set the

background with an examination of the rationale and the difficulties that are inherent with

concurrent therapy from the point of view of both the delivery of radiation and of chemotherapy.

Beyond this it will illustrate some of the gains achieved in therapy using a

concurrent treatment approach. Finally it will focus on the potential for the future that lies

in an increased understanding of the molecular players in neoplastic processes as well as

the response of malignant cells to therapy with radiation and chemotherapy. The integration

of new agents that are aimed against more specific cellular targets than either

radiation or traditional cytotoxic chemotherapy may significantly influence the success

of combined modality therapy in the future.

TREATMENT PARADIGMS

Surgical therapy as a sole modality often fails because micrometastatic disease is

already present at the time of surgery or because malignant cells are present beyond the

surgical margins of the resection. Radiation therapy is sometimes added before or after

surgical resection to decrease the possibility of local recurrence when it is felt that there

is a high enough probability of residual malignant cells being present after surgery.

However, radiation therapy as both a sole modality of treatment or as an adjuvant or

adjunctive therapy may fail to sterilize tumors because of micrometastases or because the

dose of radiation that can be safely delivered is limited by the tolerance of the surrounding

normal tissues. Certainly the explosion of new technology in the current computer age

has improved our ability to deliver further radiation in a more conformal fashion. However,

in those malignancies that have a high propensity for distant spread of disease,

delivery of higher doses of conformal radiation may not prove to be a satisfactory approach

to the problem. Unfortunately chemotherapy rarely proves to have a curative role on its

own in the treatment of solid tumors.

BIOLOGY COMPLICATES THE DELIVERY OF RADIATION
The delivery of therapeutic radiation is limited by the tolerance of the surrounding
normal tissues. Data have been compiled over many years that suggest which structures
are able to tolerate certain doses with acceptable amounts of toxicity (2). This model for
thinking about how to plan the delivery of radiation has changed considerably with the
advent of new computer- and automation-driven technologies that allow for the more
conformal delivery of dose to the gross tumor and to the clinical target volume. New
analytical tools called dose volume histograms, which allow for a definition of the dose
delivered to a percentage of an organ, have begun to replace more traditional concepts of
normal tissue tolerance. Although these technology-related advances allowfor the delivery of higher doses of radiation, this may only be an effective strategy in those
tumors whose biology makes them amenable to a local therapy as the sole modality of
treatment. Those tumors that have a predilection for the early dissemination of
micrometastases cannot be effectively treated by a local therapy alone. However, those
tumors that tend to remain localized for longer periods of time may have several biologic
reasons that underlie their resistance to radiation.

Tumor Hypoxia

Tumor Hypoxia

The equally intriguing phenomenon of tumor hypoxia has been documented to occur in a number of tumor types including cancers of the uterine cervix , head and neck , bladder as well as in soft tissue sarcomas . This is the result of inadequate blood supply to tissues that leads to the compromise of biological function and in the case of cancers this is usually related to abnormal or inadequate blood vessels, anemia, or the formation of methemoglobin or carboxyhemoglobin that will reduce the oxygen carrying capacity of the blood in smokers.

There have been several observations collected over the last few decades that suggest that tumor hypoxia plays a key role in outcome. These observations are as follows: tumors often have lower median partial pressures of oxygen than their tissues of origin ; the presence of tumor hypoxia cannot necessarily be reliably predicted by factors like stage, size, histology, or grade; tumor-to-tumor oxygen variability is often greater than intratumor oxygenation

differences , and recurrent tumors often are more poorly oxygenated than their corresponding primary tumor.

While the controversy about the exact role that anemia plays in determining outcome from radiation therapy is age old, i.e., big tumors bleed more and are more likely to spread vs tumors in anemic patients tend to be more hypoxic and hence more resistant to therapy, evidence is accumulating to suggest that reality is firmly rooted between both views. Radiosensitivity is known to be significantly limited when the partial pressure of oxygen is less than 25–30 mmHg.

It has been known for years that molecular oxygen will increase radiation-induced DNA damage through the formation of oxygen free radicals that act to inflict “indirect” damage beyond the “direct” effects of radiation on DNA . There is also substantial evidence obtained over the last few years that tumor hypoxia induces genomic changes with subsequent upregulation of genes that are linked to radiation resistance . Equally compelling are the experiments that have revealed that presence of tumor hypoxia is linked to an increased incidence of metastatic disease .
The microenvironmental signals in a hypoxic tumor environment are such that there is greater genomic instability and selection pressure to maintain those cells with increased angiogenic potential and decreased apoptotic potential. Improved understanding of this interesting phenomenon will ultimately lead to improved potential for therapeutic targeting of tumors.